Tuning Nanoparticle Interactions with Ovarian Cancer through Layer-by-Layer Modification of Surface Chemistry.
layer-by-layer
nanomedicine
nanoparticles
ovarian cancer
subcellular targeting
surface chemistry
tumor-targeting
Journal
ACS nano
ISSN: 1936-086X
Titre abrégé: ACS Nano
Pays: United States
ID NLM: 101313589
Informations de publication
Date de publication:
25 02 2020
25 02 2020
Historique:
pubmed:
24
1
2020
medline:
19
12
2020
entrez:
24
1
2020
Statut:
ppublish
Résumé
Nanoparticle surface chemistry is a fundamental engineering parameter that governs tumor-targeting activity. Electrostatic assembly generates controlled polyelectrolyte complexes through the process of adsorption and charge overcompensation utilizing synthetic polyions and natural biomacromolecules; it can yield films with distinctive hydration, charge, and presentation of functional groups. Here, we used electrostatic layer-by-layer (LbL) assembly to screen 10 different surface chemistries for their ability to preferentially target human ovarian cancer
Identifiants
pubmed: 31971772
doi: 10.1021/acsnano.9b09213
pmc: PMC7062411
mid: NIHMS1552577
doi:
Substances chimiques
Peptides
0
Polyglutamic Acid
25513-46-6
polyaspartate
26063-13-8
Hyaluronic Acid
9004-61-9
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
2224-2237Subventions
Organisme : NIBIB NIH HHS
ID : F32 EB017614
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA014051
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM008334
Pays : United States
Références
J Clin Oncol. 2015 Sep 10;33(26):2841-7
pubmed: 26240233
Biomacromolecules. 2003 Sep-Oct;4(5):1184-90
pubmed: 12959582
Nanomedicine (Lond). 2012 May;7(5):619-22
pubmed: 22630144
Nat Commun. 2017 Oct 3;8(1):777
pubmed: 28974673
Pharm Res. 2010 May;27(5):735-8
pubmed: 20198409
ACS Nano. 2019 May 28;13(5):5623-5634
pubmed: 30986034
Am J Pathol. 2010 Sep;177(3):1053-64
pubmed: 20651229
Bioconjug Chem. 2004 Jul-Aug;15(4):897-900
pubmed: 15264879
Cancer Res. 1984 Aug;44(8):3584-92
pubmed: 6744281
Angew Chem Int Ed Engl. 2014 May 12;53(20):5093-6
pubmed: 24700480
J Control Release. 2000 Mar 1;65(1-2):271-84
pubmed: 10699287
Int J Nanomedicine. 2012;7:5577-91
pubmed: 23144561
J Biomater Sci Polym Ed. 2001;12(11):1191-205
pubmed: 11853386
Small. 2010 Jan;6(1):12-21
pubmed: 19844908
Nat Commun. 2017 Aug 28;8(1):365
pubmed: 28848242
Cell Metab. 2018 Jun 05;27(6):1249-1262.e4
pubmed: 29706565
Proteomics. 2009 May;9(10):2820-35
pubmed: 19415654
Expert Rev Proteomics. 2011 Apr;8(2):263-77
pubmed: 21501018
N Engl J Med. 1996 Dec 26;335(26):1950-5
pubmed: 8960474
ACS Nano. 2014 Aug 26;8(8):8374-82
pubmed: 25100313
Proc Natl Acad Sci U S A. 2016 Oct 11;113(41):11453-11458
pubmed: 27663731
Nat Rev Mater. 2017;2:
pubmed: 29075517
Cancer Res. 1986 Dec;46(12 Pt 1):6387-92
pubmed: 2946403
Adv Funct Mater. 2016 Feb 16;26(7):991-1003
pubmed: 27134622
J Ovarian Res. 2009 Dec 24;2:21
pubmed: 20034397
J Clin Oncol. 2001 Feb 15;19(4):1001-7
pubmed: 11181662
J Cell Physiol. 2019 Mar;234(3):2134-2142
pubmed: 30317611
Cancer Res. 1993 Mar 15;53(6):1281-5
pubmed: 8383007
Nano Lett. 2009 May;9(5):1909-15
pubmed: 19344179
J Am Chem Soc. 2012 Feb 1;134(4):2139-47
pubmed: 22191645
Clin Cancer Res. 2017 Mar 1;23(5):1263-1273
pubmed: 27573169
Nat Med. 2011 Sep 18;17(10):1315-9
pubmed: 21926976
Nat Rev Clin Oncol. 2010 Nov;7(11):653-64
pubmed: 20838415
J Clin Epidemiol. 2014 Aug;67(8):850-7
pubmed: 24831050
Nat Mater. 2009 Jul;8(7):543-57
pubmed: 19525947